Libra Therapeutics is a technology company.
Libra Therapeutics has raised $29.0M across 1 funding round.
Libra Therapeutics has raised $29.0M in total across 1 funding round.
Libra Therapeutics has raised $29.0M in total across 1 funding round.
Libra Therapeutics's investors include AMR Action Fund, Mission BioCapital.
Libra Therapeutics is a San Diego-based biotechnology company developing novel small molecule therapeutics to restore cellular balance in neurodegenerative diseases such as ALS, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's.[1][2][3] Its lead program targets TRPML1 to enhance lysosomal function and autophagy, clearing toxic proteins and reducing neurotoxic protein production, with Phase 1 clinical trials on track for 2025; the pipeline includes three small molecule programs serving patients with CNS and peripheral degenerative disorders.[1][2][3] Operating as a fully virtual company without in-house labs, Libra leverages a global network of contract research organizations (CROs) for all R&D, enabling efficient progression from screening to IND-enabling studies while raising $29M in Series A funding.[1][2]
Founded in 2019 (with some sources noting establishment in 2020), Libra Therapeutics emerged from a mission to address neurodegeneration, driven by the team's firsthand experience with its debilitating effects.[1][2][3][4] Isaac Veinbergs, Ph.D., serves as President and CEO, bringing over 25 years in biopharma R&D and leadership from roles at Acadia Pharmaceuticals, FoldRx, Amgen, Elan, Sanofi Genzyme, and others, where he advanced neurodegeneration programs to INDs and NDAs; his molecular pathology background from UCSD underscores the company's focus.[3][4] Early traction came via proprietary technologies, innovative assays from CROs like Axxam, and hit compounds from screening campaigns, enabling a "plug and play" virtual model that rapidly built a three-program pipeline without physical infrastructure.[1][2]
Libra rides the wave of lysosomal dysfunction and autophagy enhancement as key trends in neurodegeneration, where protein aggregation drives diseases like ALS and Parkinson's amid a market projected to exceed $50B by 2030 due to aging populations.[3][4] Timing aligns with advances in small molecule screening and virtual biotech models, reducing barriers for nimble players amid Big Pharma's neuroscience resurgence post-failures in traditional approaches.[1][2] Favorable forces include CRO globalization lowering costs and AI-driven discovery accelerating hits, positioning Libra to influence the ecosystem by validating biomarker strategies and potentially licensing assets to larger firms seeking disease-modifying therapies.[2]
Libra's Phase 1 entry for its TRPML1 program in 2025 marks a pivotal inflection, with pipeline expansion into ALS, Alzheimer's, and beyond likely drawing partnerships or further funding as biomarkers de-risk clinical readouts.[1][2] Trends like precision autophagy modulators and virtual biotechs will propel growth, evolving Libra's influence from early-stage innovator to potential acquirer in a neurodegeneration space hungry for breakthroughs. This cellular balance restoration hooks back to its founding ethos, promising tangible progress against unmet needs in brain health.[3][4]
Libra Therapeutics has raised $29.0M across 1 funding round. Most recently, it raised $29.0M Series A in September 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2020 | $29.0M Series A | AMR Action Fund, Mission BioCapital |